Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Pyrotinib + capecitabine extends OS in metastatic breast cancer

Pyrotinib + capecitabine extends OS in metastatic breast cancer

10 Jan 2022 bởiRoshini Claire Anthony

Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.

10 Jan 2022
Entinostat-exemestane combo yields survival benefit for HR+ advanced BC

Entinostat-exemestane combo yields survival benefit for HR+ advanced BC

04 Jan 2022 bởiAudrey Abella

In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.

04 Jan 2022